Related Experiment Videos
Heavy chain disease
Thomas E Witzig1, Dietlind L Wahner-Roedler
1Division of Hematology, Mayo Clinic and Mayo Foundation, 200 SW First Street, Rochester, MN 55905, USA. witzig@mayo.edu
Insights
Heavy chain diseases (HCDs) are rare B-cell cancers where malignant cells produce immunoglobulin heavy chains without light chains. Alpha-HCD presents as intestinal malabsorption, while gamma- and mu-HCD are associated with non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Heavy chain diseases (HCDs) are rare B-cell malignancies characterized by monoclonal immunoglobulin heavy chain (HC) production without associated light chains.
- Three types exist: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD), defined by the HC class produced.
Purpose of the Study:
- To describe the characteristics, diagnosis, and treatment of heavy chain diseases.
- To differentiate alpha-HCD from gamma- and mu-HCD based on clinical presentation and association with other B-cell malignancies.
Main Methods:
- Review of existing literature and case studies on heavy chain diseases.
- Analysis of diagnostic criteria and treatment strategies for different HCD subtypes.
Main Results:
- Alpha-HCD is the most common type, often presenting as intestinal malabsorption in young adults from Mediterranean regions.
- Gamma- and mu-HCD are rare, typically found in patients with B-cell non-Hodgkin's lymphoma (NHL) producing abnormal HC, and may be associated with monoclonal gammopathy of undetermined significance (MGUS).
- Treatment for alpha-HCD involves antibiotics, nutrition, hygiene, and potentially chemotherapy for aggressive forms or lack of response.
- Chemotherapy is indicated for patients with gamma- or mu-HCD associated with NHL or MGUS.
Conclusions:
- Heavy chain diseases require specific diagnostic and treatment approaches based on the subtype.
- Screening serum and urine in lymphoplasmacytoid NHL patients may improve detection of gamma- and mu-HCD.
- Early diagnosis and appropriate treatment, including chemotherapy for certain subtypes, are crucial for managing these rare B-cell malignancies.
Abstract:
The heavy chain diseases (HCDs) are rare B-cell malignancies that are distinguished by the production of a monoclonal immunoglobulin heavy chain (HC) without an associated light chain by the malignant B-cells. There are three types of HCD defined by the class of immunoglobulin (Ig) HC produced: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD). Alpha-HCD is the most common and occurs most commonly as intestinal malabsorption in a young adult from a country bordering the Mediterranean Sea. Treatment consists of antibiotics and improved nutrition and hygiene. Surgery is occasionally required for patients with bulky masses at risk for bowel perforation. If there is no response to antibiotics or if aggressive non-Hodgkin's lymphoma (NHL) is diagnosed, the patient should be treated with chemotherapy. Gamma- and mu-HCD are rare and essentially are found in patients with a B-cell NHL that produces an abnormal Ig heavy chain. These patients occasionally may be diagnosed with a monoclonal gammopathy of undetermined significance (MGUS). Patients with MGUS with NHL should be administered chemotherapy. Screening the serum and urine of patients with lymphoplasmacytoid NHL would likely identify more patients with gamma- or mu-HCD.